Insights from ELCC 2024
ELCC 2024 Insights: "BECOME Study - Becotarug (JMT101) Combined With Osimertinib for Locally Advanced or Metastatic NSCLC Harboring EGFR ex20ins Mutations"
By
Insights from ELCC 2024
FEATURING
Li Zhang
By
Insights from ELCC 2024
FEATURING
Li Zhang
Comments 0
Login to view comments.
Click here to Login
